Form 4: NeuroPace CMO Martha Morrell's Tax Withholding

NeuroPace Inc.'s Chief Medical Officer, Martha Morrell, reported the disposition of 1,338 common shares to cover tax obligations related to a restricted stock unit vesting.

Summary

• Martha Morrell, Chief Medical Officer of NeuroPace Inc., reported a transaction on December 3, 2025.
• The transaction involved the disposition of 1,338 shares of NeuroPace Inc. Common Stock.
• These shares were withheld by the company to satisfy tax withholding obligations associated with the vesting of a restricted stock unit award.
• The shares were valued at $16.66 per share for the purpose of this transaction.
• Following this transaction, Martha Morrell beneficially owns 78,734 shares of NeuroPace Inc. Common Stock.

Sentiment

Score: 5

Explanation: The transaction is a routine tax withholding event for executive compensation and does not indicate a positive or negative sentiment towards the company's performance or outlook.

Future Outlook

NA

Industry Context

This is a routine insider transaction related to compensation and tax obligations, which does not provide specific insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Minimal direct impact on shareholders as this is a routine, non-discretionary transaction related to executive compensation and tax obligations.
• No direct impact on employees, customers, suppliers, or creditors is indicated by this filing.

Key Dates

Keywords

NeuroPace Inc, NPCE, Martha Morrell, Chief Medical Officer, Form 4, SEC filing, stock transaction, tax withholding, restricted stock units, insider transaction